Yunnan Biovalley Pharmaceutical (BJ:833266)2023-02-23 16:00Financial Performance - The company expects a net loss for the reporting period, estimated between -47.64 million to -58.56 million CNY, compared to a profit of 83.49 million CNY in the same period last year[4]. - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the official annual report[6]. Sales and Expenses - The increase in sales expenses is attributed to the impact of the pandemic, medical insurance payment reforms, and policies on traditional Chinese medicine procurement, leading to a focus on market expansion and stability[5]. Shareholder Communication - The company is actively communicating with its major shareholder regarding the repayment of funds and is assessing credit risk for outstanding debts[5].